Autoimmune Nature of Influenza Atherogenicity

Gurevich, V. S.; Pleskov, V M; Levaya, Margarita V.

doi:10.1196/annals.1313.092

Cited by 18 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another current hypothesis is that direct colonization of the vessel wall initiates local cell autoimmune reactions by activation of antigen-presenting cells. 17 …”

Section: Influenza Among Patients With Cvdmentioning

confidence: 99%

Influenza Vaccination as Secondary Prevention for Cardiovascular Disease

Davis¹,

Taubert²,

Benin³

et al. 2006

Circulation

105

View full text Add to dashboard Cite

Abstract-Evidence from cohort studies and a randomized clinical trial indicates that annual vaccination against seasonal influenza prevents cardiovascular morbidity and all-cause mortality in patients with cardiovascular conditions. The American Heart Association and American College of Cardiology recommend influenza immunization with inactivated vaccine (administered intramuscularly) as part of comprehensive secondary prevention in persons with coronary and other atherosclerotic vascular disease (Class I, Level B). Immunization with live, attenuated vaccine (administered intranasally) is not currently recommended for persons with cardiovascular conditions. It is important to note that influenza vaccination coverage levels overall and in this population remain well below national goals and are marked by disparities across different age and ethnic groups. One of the barriers to vaccination for patients with cardiovascular disease is that cardiology practices frequently do not stock and administer influenza vaccine. Healthcare providers who treat individuals with cardiovascular disease can help improve influenza vaccination coverage rates by providing and strongly recommending vaccination to their patients before and throughout the influenza season.

show abstract

“…Another current hypothesis is that direct colonization of the vessel wall initiates local cell autoimmune reactions by activation of antigen-presenting cells. 17 …”

Section: Influenza Among Patients With Cvdmentioning

confidence: 99%

Influenza Vaccination as Secondary Prevention for Cardiovascular Disease

Davis¹,

Taubert²,

Benin³

et al. 2006

Circulation

105

View full text Add to dashboard Cite

show abstract

“…One current hypothesis is that the inflammatory response of the body to viral infection leads to production of autoantibodies to modified low-density lipoprotein, which causes the development and progression of atherosclerotic vascular injury. Another current hypothesis is that direct colonization of the vessel wall initiates local cell autoimmune reactions by activation of antigen-presenting cells (17).…”

Section: Influenza Among Patients With Cvdmentioning

confidence: 99%

Influenza Vaccination as Secondary Prevention for Cardiovascular Disease

Davis

Taubert²,

Benin³

et al. 2006

Journal of the American College of Cardiology

161

View full text Add to dashboard Cite

Evidence from cohort studies and a randomized clinical trial indicates that annual vaccination against seasonal influenza prevents cardiovascular morbidity and all-cause mortality in patients with cardiovascular conditions. The American Heart Association and American College of Cardiology recommend influenza immunization with inactivated vaccine (administered intramuscularly) as part of comprehensive secondary prevention in persons with coronary and other atherosclerotic vascular disease (Class I, Level B). Immunization with live, attenuated vaccine (administered intranasally) is not currently recommended [corrected] for persons with cardiovascular conditions. It is important to note that influenza vaccination coverage levels overall and in this population remain well below national goals and are marked by disparities across different age and ethnic groups. One of the barriers to vaccination for patients with cardiovascular disease is that cardiology practices frequently do not stock and administer influenza vaccine. Healthcare providers who treat individuals with cardiovascular disease can help improve influenza vaccination coverage rates by providing and strongly recommending vaccination to their patients before and throughout the influenza season.

show abstract

“…Genetic studies can potentially address this issue using a Mendelian randomization approach. In support of these genetic association studies, inflammatory diseases have also been shown to strongly associate with cardiovascular diseases [19]. By contrast, a causal role for a cytokine upstream of CRP, interleukin (IL)-6 [15,16], was elegantly demonstrated by two independent research consortia [17 && ,18 && ].…”

Section: Inflammation and Atherosclerosismentioning

confidence: 99%

Novel anti-inflammatory strategies in atherosclerosis

Valk

Wijk

Stroes

2012

Current Opinion in Lipidology

View full text Add to dashboard Cite

Anti-inflammatory therapies hold great promise in cardiovascular prevention regimens; however, atherosclerosis is a chronic disease, and systemic long-term use of anti-inflammatory agents carries the risk of complications arising from immunosuppression. In order to successfully add immunosuppressive drugs to our routine armament, we need to identify high-risk patients who benefit from anti-inflammatory treatment, increase our insight into the inflammatory pathogenesis of atherogenesis, and find safe and effective compounds capable of directly suppressing plaque inflammation.

show abstract

Autoimmune Nature of Influenza Atherogenicity

Cited by 18 publications

References 30 publications

Influenza Vaccination as Secondary Prevention for Cardiovascular Disease

Influenza Vaccination as Secondary Prevention for Cardiovascular Disease

Influenza Vaccination as Secondary Prevention for Cardiovascular Disease

Novel anti-inflammatory strategies in atherosclerosis

Contact Info

Product

Resources

About